ASLAN Pharmaceuticals Limited (ASLN)
- Previous Close
0.4480 - Open
0.4407 - Bid 0.4200 x 300
- Ask 0.4400 x 100
- Day's Range
0.4113 - 0.4700 - 52 Week Range
0.3920 - 4.6900 - Volume
641,108 - Avg. Volume
1,216,801 - Market Cap (intraday)
9.397M - Beta (5Y Monthly) 1.47
- PE Ratio (TTM)
-- - EPS (TTM)
-2.7500 - Earnings Date Apr 29, 2024 - May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.50
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
aslanpharma.comRecent News: ASLN
Performance Overview: ASLN
Trailing total returns as of 4/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASLN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASLN
Valuation Measures
Market Cap
9.40M
Enterprise Value
14.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.57
Price/Book (mrq)
--
Enterprise Value/Revenue
1.25
Enterprise Value/EBITDA
-0.38
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.71%
Return on Equity (ttm)
--
Revenue (ttm)
12M
Net Income Avi to Common (ttm)
-44.22M
Diluted EPS (ttm)
-2.7500
Balance Sheet and Cash Flow
Total Cash (mrq)
21.25M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-30.01M
Research Analysis: ASLN
Company Insights: ASLN
ASLN does not have Company Insights